Accelerating NDA filing through faster carcinogenicity assessment
Drug Discovery World
MAY 10, 2023
This stage is more highly regulated and consists of both preclinical testing and clinical trials. These guidelines are in place to evaluate a pharmaceutical’s potential health risks, including genotoxicity, immunotoxicity, and reproductive toxicity. Toxicologic Pathology. 2011;39(4):716-744.
52 
Let's personalize your content